Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or Wit… (NCT01701219) | Clinical Trial Compass
CompletedPhase 4
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
United States56 participantsStarted 2013-01
Plain-language summary
This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Presence of bacteremia due solely to:
✓. Male or female ≥ 18 years of age.
✓. If female of childbearing potential must be willing to practice sexual abstinence or dual methods of contraception during treatment and for at least 30 days after the last dose of study drug.
✓. Expectation of survival for at least 2 months.
Exclusion criteria
✕. For subjects in Cohort A: previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results.
✕. For subjects in Cohort B: previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence.
✕. Previous episode of S. aureus bacteremia within 3 months.
✕. Known left-sided endocarditis or prosthetic heart valve.
✕. Osteomyelitis or prosthetic joint infection except new onset nonhardware-associated vertebral osteomyelitis.
✕. History of any hypersensitivity or allergic reaction to any β-lactam antibacterial agent.
✕. Evidence of significant hepatic, hematologic, or immunologic impairment.
✕
What they're measuring
1
Evaluate the safety of ceftaroline fosamil in adult Subjects (≥ 18 years of age) with Staphylococcus aureus Bacteremia or with MRSA Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment
Timeframe: 60 days following completion of antibacterial therapy and discharge from the hospital, anticipated between 74 to 119 days